Testing Rewards for Stopping Cannabis Use in People With Depression
Tests rewards for stopping cannabis use in adults with depression and cannabis use disorder.
Plain-language title generated from the registry record
Registry title: Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression
Key facts
- Where
- Toronto, CanadaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Source: NCT04935619, who can take part
Where in Canada
- Centre for Addiction and Mental HealthToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre for Addiction and Mental Health
- Trial code
- NCT04935619
- Record updated
- 24 February 2025
- Original description
The prevalence of major depressive disorder (MDD) is ~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.Read full original descriptionShow less
Effects of Extended Cannabis Abstinence on Clinical and Cognitive Outcomes in Patients With Co-Morbid Major Depressive and Cannabis Use Disorders
The prevalence of major depressive disorder (MDD) is ~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.
Inclusion: All participants must be between the ages 18-55; Meet SCID for DSM-5 diagnostic criteria for cannabis use disorder, moderate to severe; Meet SCID for DSM-5 diagnostic criteria for Major Depressive Disorder; Be an outpatient receiving a stable dose of antidepressant medication for at least three months (to ensure stability of depressive symptoms; Have a Hamilton Depression Rating Scale (HDRS-17) at baseline assessment in the range of 12-25; Have a Full-Scale IQ ≥ 80 as determined by the WTAR; Be a non-treatment seeking cannabis user; Evidence of sufficient motivation and effort as measured by a Test of Memory Malingering (TOMM) score ≥ 45.
Exclusion: Meets criteria for substance use disorder of alcohol or other illicit substances within the past 6 months (with the exception of cannabis, nicotine, or caffeine); Psychotic disorder diagnosis (e.g. schizoaffective disorder, major depression with psychotic features) as determined by the SCID; Meet SCID for DSM-5 diagnostic criteria for Bipolar Disorder; Positive urine screen for illicit substances other than cannabis, nicotine, or caffeine; Current suicidal or homicidal ideation; Treatment seeking for cannabis use; Head Injury> 5 minutes LOC; Exceed upper and lower cut-offs on HSRD-17 (See Inclusion Criteria).